DSWL [DESWELL INDUSTRIES] SD: (Original Filing)
[]
RCON [Recon Technology] 6-K: (Original Filing)
[SUBJECT TO LEGAL REVIEW AND COMMITMENT COMMITTEE APPROVAL CONFIDENTIAL May 7, 2020 VIA ELECTRONIC DELIVERY Mr. Shenping Yin Co-founder & CEO Recon Technology, Ltd. King Long International Mansion Building C Room 1902 9 Fulin Road Chaoyang District Beijing 100107, China Dear Mr. Yin: Agreement Maxim ]
RCON [Recon Technology] 6-K: SUBJECT TO LEGAL REVIEW AND COMMITMENT COMMITTEE APPROVAL
[SUBJECT TO LEGAL REVIEW AND COMMITMENT COMMITTEE APPROVAL CONFIDENTIAL May 7, 2020 VIA ELECTRONIC DELIVERY Mr. Shenping Yin Co-founder & CEO Recon Technology, Ltd. King Long International Mansion Building C Room 1902 9 Fulin Road Chaoyang District Beijing 100107, China Dear Mr. Yin: Agreement Maxim ]
CCCL [China Ceramics] 6-K: (Original Filing)
[china ceramics co., ltd. Holder Initial Exercise Date Termination Date Company Section 1 Definitions Purchase Agreement Section 2 Exercise Notice of Exercise a) 1 Exercise Price Exercise Price b) Cashless Exercise c) 2 Bid Price “ VWAP “ 3 d) Mechanics of Exercise DWAC Standard Settlement Period i. ]
CCCL [China Ceramics] 6-K: china ceramics co., ltd. Holder Initial Exercise Date
[china ceramics co., ltd. Holder Initial Exercise Date Termination Date Company Section 1 Definitions Purchase Agreement Section 2 Exercise Notice of Exercise a) 1 Exercise Price Exercise Price b) Cashless Exercise c) 2 Bid Price “ VWAP “ 3 d) Mechanics of Exercise DWAC Standard Settlement Period i. ]
TOUR [Tuniu] 20-F: (Original Filing)
[] [Description of rights of each class of securities Class A Ordinary Shares Type and Class of Securities (Item 9.A.5 of Form 20-F) Each Class A ordinary share has a par value of US$0.0001 per share. The number of Class A ordinary shares that have been issued as of the last day of the financial year]
SVA [SINOVAC BIOTECH] 6-K: (Original Filing)
[Sinovac Secures $15 Million in Funding to Accelerate COVID-19 Vaccine Development BEIJING, May 22, 2020 -- (BUSINESS WIRE) -- Sinovac Biotech Ltd. (“Sinovac” or the “Company”) (NASDAQ: SVA), a leading provider of biopharmaceutical products in China, today announced a transaction in which Advantech C]
